PLAY PODCASTS
Pure Global: Brazil's AI MedTech Gold Rush - Unlocking ANVISA's New Fast-Track

Pure Global: Brazil's AI MedTech Gold Rush - Unlocking ANVISA's New Fast-Track

LATAM MedTech Insights · Ran Chen

March 7, 20262m 14s

Audio is streamed directly from the publisher (episodes.captivate.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA, RDC 989, which establishes a new fast-track approval pathway for AI-driven diagnostic software. This is a pivotal moment for the MedTech industry in Latin America, promising to accelerate innovation and market access. However, this opportunity comes with significant new hurdles. The regulation introduces complex requirements for predetermined change control plans, mandates the use of local Brazilian patient data for algorithm validation, and enforces stricter cybersecurity protocols. We explore the strategic implications for foreign and domestic manufacturers aiming to capitalize on this new landscape. A real-world example. a U.S.-based SaMD company has its AI-powered radiological tool approved by the FDA. They targeted Brazil for their next expansion, but ANVISA's new RDC 989 just made their existing clinical data insufficient. They now face the urgent challenge of conducting a local validation study to qualify for the fast-track process, a costly and time-consuming roadblock they didn't anticipate. Key Takeaways: 1. What exactly is a Predetermined Change Control Plan (PCCP) and how do I create one for ANVISA? 2. Does my existing clinical data from US or EU studies meet the new requirements for Brazil? 3. What are the specific cybersecurity and data privacy mandates under RDC 989? 4. How can I initiate a local clinical validation study in Brazil efficiently? 5. What is the timeline for compliance for products already under review by ANVISA? 6. How does this new fast-track pathway change the overall cost and timeline for market entry? 7. Will this regulation give local Brazilian MedTech startups a competitive advantage? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, helping you navigate complex regulations like RDC 989 to ensure your products reach the market efficiently. To understand how we can help with your market access strategy in Brazil and beyond, contact us at [email protected] or visit https://pureglobal.com/.